ERBB2 and lung carcinoma: 37315265 37315265 Ganti AK, Rothe M, Mangat PK et al (2023) Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.